NCT07306598 · RECRUITING
[18F]NIDF PET Imaging in Tau-related Diseases
This study is testing a new PET brain imaging tracer called [18F]NIDF, which is designed to detect abnormal tau protein in the living brain. Tau tangles are a hallmark of Alzheimer's and related diseases. The goal is to see whether this tracer is safe and whether it produces clearer, more accurate images than existing tau-PET tracers. The phase is unspecified, so this appears to be an early-stage human safety and feasibility study.
You may qualify if
- Between 18 and 90 years old;
- No gender limitation;
- Clinical diagnositic rerults supported the diagnosis of neurodegeneration, and there was no evidence of other neurological diseases;
- Healthy participants or patients with probable Alzheimer's disease or with dementia due to other causes;
- Informed consent signed in person by the subject or his legal guardian or caregiver.
You're excluded if
- Has allergy to [18F]NIDF or any of its excipients;
- Incapable of providing written informed consent or lacking a legally authorized representative (LAR) to provide informed consent ;
- Unwilling or unable to undergo PET scans tracer injections;
- Any condition that, in the Investigator's opinion, could increase the risk to the participant, limit the participant's ability to tolerate the research procedures, or interfere with the collection/analysis of the data (e.g., renal or liver failure, advanced cancer);
- Received an experimental drug or device within 1 month (whose efficacy or safety is unclear);
- Have other serious neurological disorders, or gastrointestinal, cardiovascular, liver, kidney, blood system, tumor, endocrine, respiratory, immune deficiency, and other serious diseases;
- Women who are currently pregnant or breastfeeding.
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2025-12-29